Citation: | Please cite this article as: ZHOU Y, LONG MY, CHEN ZQ, HUANG JW, QIN ZB, LI L. Downregulation of miR-181a-5p alleviates oxidative stress and inflammation in coronary microembolization-induced myocardial damage by directly targeting XIAP. J Geriatr Cardiol 2021; 18(6): 426−439. DOI: 10.11909/j.issn.1671-5411.2021.06.007 |
[1] |
Erbel R, Heusch G. Coronary microembolization. J Am Coll Cardiol 2000; 36: 22−24. doi: 10.1016/S0735-1097(00)00708-7
|
[2] |
Salem SA, Haji S, Garg N, et al. Occlusion of right coronary artery by microembolization caused by excessive diagnostic catheter manipulation. Ann Transl Med 2018; 6: 20. doi: 10.21037/atm.2017.12.22
|
[3] |
Heusch G, Skyschally A, Kleinbongard P. Coronary microembolization and microvascular dysfunction. Int J Cardiol 2018; 258: 17−23. doi: 10.1016/j.ijcard.2018.02.010
|
[4] |
Wang Y, Zhao HW, Wang CF, et al. Incidence, predictors, and prognosis of coronary slow-flow and no-reflow phenomenon in patients with chronic total occlusion who underwent percutaneous coronary intervention. Ther Clin Risk Manag 2020; 16: 95−101. doi: 10.2147/TCRM.S233512
|
[5] |
Kalyoncuoglu M, Biter Hİ, Ozturk S, et al. Predictive accuracy of lymphocyte-to-monocyte ratio and monocyte-to-high-density-lipoprotein-cholesterol ratio in determining the slow flow/no-reflow phenomenon in patients with non-ST-elevated myocardial infarction. Coron Artery Dis 2020; 31: 518−526. doi: 10.1097/MCA.0000000000000848
|
[6] |
Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356: 830−840. doi: 10.1056/NEJMra061889
|
[7] |
Nakanishi K, Daimon M. Coronary slow flow and subclinical left ventricular dysfunction. Int Heart J 2019; 60: 495−496. doi: 10.1536/ihj.19-152
|
[8] |
Heusch G. The regional myocardial flow-function relationship: a framework for an understanding of acute ischemia, hibernation, stunning and coronary microembolization. 1980. Circ Res 2013; 112: 1535−1537. doi: 10.1161/CIRCRESAHA.113.301446
|
[9] |
Chen ZW, Qian JY, Ma JY, et al. TNF-α-induced cardiomyocyte apoptosis contributes to cardiac dysfunction after coronary microembolization in mini-pigs. J Cell Mol Med 2014; 18: 1953−1963. doi: 10.1111/jcmm.12342
|
[10] |
Chen A, Chen Z, Zhou Y, et al. Rosuvastatin protects against coronary microembolization-induced cardiac injury via inhibiting NLRP3 inflammasome activation. Cell Death Dis 2021; 12: 78. doi: 10.1038/s41419-021-03389-1
|
[11] |
Su Q, Lv X, Ye Z. Ligustrazine attenuates myocardial injury induced by coronary microembolization in rats by activating the PI3K/Akt pathway. Oxid Med Cell Longev 2019; 2019: 6791457. doi: 10.1155/2019/6791457
|
[12] |
Zhu L, Li N, Sun L, et al. Non-coding RNAs: the key detectors and regulators in cardiovascular disease. Genomics 2021; 113: 1233−1246. doi: 10.1016/j.ygeno.2020.10.024
|
[13] |
Arabian M, Mirzadeh Azad F, Maleki M, et al. Insights into role of microRNAs in cardiac development, cardiac diseases, and developing novel therapies. Iran J Basic Med Sci 2020; 23: 961−969. doi: 10.22038/ijbms.2020.40974.10015
|
[14] |
Zhou H, Ni WJ, Meng XM, et al. MicroRNAs as regulators of immune and inflammatory responses: potential therapeutic targets in diabetic nephropathy. Front Cell Dev Biol 2021; 8: 618536. doi: 10.3389/fcell.2020.618536
|
[15] |
Colpaert RMW, Calore M. Epigenetics and microRNAs in cardiovascular diseases. Genomics 2021; 113: 540−551. doi: 10.1016/j.ygeno.2020.12.042
|
[16] |
Ye H, Xu G, Zhang D, et al. The protective effects of the miR-129-5p/keap-1/Nrf2 axis on Ang II-induced cardiomyocyte hypertrophy. Ann Transl Med 2021; 9: 154. doi: 10.21037/atm-20-8079
|
[17] |
Qu Y, Zhang J, Zhang J, et al. MiR-708-3p alleviates inflammation and myocardial injury after myocardial infarction by suppressing ADAM17 expression. Inflammation. Published Online First: 25 January 2021. DOI: 10.1007/s10753-020-01404-9.
|
[18] |
Su Q, Lv X, Ye Z, et al. The mechanism of miR-142-3p in coronary microembolization-induced myocardiac injury via regulating target gene IRAK-1. Cell Death Dis 2019; 10: 61. doi: 10.1038/s41419-019-1341-7
|
[19] |
Zhu HH, Wang XT, Sun YH, et al. MicroRNA-486-5p targeting PTEN protects against coronary microembolization-induced cardiomyocyte apoptosis in rats by activating the PI3K/AKT pathway. Eur J Pharmacol 2019; 855: 244−251. doi: 10.1016/j.ejphar.2019.03.045
|
[20] |
Sun X, Sit A, Feinberg MW. Role of miR-181 family in regulating vascular inflammation and immunity. Trends Cardiovasc Med 2014; 24: 105−112. doi: 10.1016/j.tcm.2013.09.002
|
[21] |
Sun YH, Su Q, Li L, et al. Expression of p53 in myocardium following coronary microembolization in rats and its significance. J Geriatr Cardiol 2017; 14: 292−300. doi: 10.11909/j.issn.1671-5411.2017.05.007
|
[22] |
Heusch G. The coronary circulation as a target of cardioprotection. Circ Res 2016; 118: 1643−1658. doi: 10.1161/CIRCRESAHA.116.308640
|
[23] |
Malyar NM, Lerman LO, Gössl M, et al. Relation of nonperfused myocardial volume and surface area to left ventricular performance in coronary microembolization. Circulation 2004; 110: 1946−1952. doi: 10.1161/01.CIR.0000143631.15077.0F
|
[24] |
Dörge H, Schulz R, Belosjorow S, et al. Coronary microembolization: the role of TNF-alpha in contractile dysfunction. J Mol Cell Cardiol 2002; 34: 51−62. doi: 10.1006/jmcc.2001.1489
|
[25] |
Li S, Zhong S, Zeng K, et al. Blockade of NF-kappaB by pyrrolidine dithiocarbamate attenuates myocardial inflammatory response and ventricular dysfunction following coronary microembolization induced by homologous microthrombi in rats. Basic Res Cardiol 2010; 105: 139−150. doi: 10.1007/s00395-009-0067-6
|
[26] |
Su Q, Li L, Sun Y, et al. Effects of the TLR4/Myd88/NF-kappaB signaling pathway on NLRP3 inflammasome in coronary microembolization-induced myocardial injury. Cell Physiol Biochem 2018; 47: 1497−1508. doi: 10.1159/000490866
|
[27] |
Ambros V. MicroRNAs: tiny regulators with great potential. Cell 2001; 107: 823−826. doi: 10.1016/S0092-8674(01)00616-X
|
[28] |
Ke XS, Liu CM, Liu DP, et al. MicroRNAs: key participants in gene regulatory networks. Curr Opin Chem Biol 2003; 7: 516−523. doi: 10.1016/S1367-5931(03)00075-9
|
[29] |
Kong B, Qin Z, Ye Z, et al. MicroRNA-26a-5p affects myocardial injury induced by coronary microembolization by modulating HMGA1. J Cell Biochem 2019; 120: 10756−10766. doi: 10.1002/jcb.28367
|
[30] |
Qin S, Yang C, Zhang B, et al. XIAP inhibits mature Smac-induced apoptosis by degrading it through ubiquitination in NSCLC. Int J Oncol 2016; 49: 1289−1296. doi: 10.3892/ijo.2016.3634
|
[31] |
Estornes Y, Bertrand MJM. IAPs, regulators of innate immunity and inflammation. Semin Cell Dev Biol 2015; 39: 106−114. doi: 10.1016/j.semcdb.2014.03.035
|
[32] |
Lu M, Qin X, Yao J, et al. MiR-134-5p targeting XIAP modulates oxidative stress and apoptosis in cardiomyocytes under hypoxia/reperfusion-induced injury. IUBMB Life 2020; 72: 2154−2166. doi: 10.1002/iub.2351
|
[33] |
Zhao R, Yu Q, Hou L, et al. Cadmium induces mitochondrial ROS inactivation of XIAP pathway leading to apoptosis in neuronal cells. Int J Biochem Cell Biol 2020; 121: 105715. doi: 10.1016/j.biocel.2020.105715
|
[34] |
Zilu S, Qian H, Haibin W, et al. Effects of XIAP on high fat diet-induced hepatic steatosis: a mechanism involving NLRP3 inflammasome and oxidative stress. Aging 2019; 11: 12177−12201. doi: 10.18632/aging.102559
|
[35] |
Zheng J, Long M, Qin Z, et al. Nicorandil inhibits cardiomyocyte apoptosis and improves cardiac function by suppressing the HtrA2/XIAP/PARP signaling after coronary microembolization in rats. Pharmacol Res Perspect 2021; 9: e00699. doi: 10.1002/prp2.699
|